Evidence map›Paper›PMID 35131974›Full record

Trial reportCancer nursing

Routine Catheter Lock Solutions in Pediatric Cancer Care: A Pilot Randomized Controlled Trial of Heparin vs Saline.

Amanda J Ullman, Rachel Edwards, Rick Walker, John Roy, Andrew Paton, Claire M Rickard, Marie Cooke, Natalie Bradford, Victoria Gibson, Paula Cattanach and 5 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Cancer nursing. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Amanda J UllmanAuthor Affiliations: School of Nursing, Midwifery and Social Work, The University of Queensland (Drs Ullman, Rickard, and Paterson, and Mss Takashima and Kleidon), St Lucia; Queensland Children's Hospital, Children's Health Queensland Hospital and Health Service (Drs Ullman, Walker, Roy, Bradrod, Cattanach, and Paterson; Mss Edwards, Gibson, Takashima, and Kleidon; and Mr Paton), South Brisbane; School of Nursing and Midwifery, Menzies Health Institute Queensland, Griffith University (Drs Ullman, Rickard, Cooke, Cattanach, Paterson, and Keogh, and Mss Edwards, Gibson, and Kleidon), Nathan; Herston Infectious Disease Institute, Metro North Hospitals and Health Service (Dr Rickard), Brisbane, Queensland; Centre for Healthcare Transformation, Queensland University of Technology (Drs Bradford and Keogh), Brisbane; Centre for Applied Health Economics, Menzies Health Institute Queensland, Griffith University (Dr Byrnes), Nathan, Australia; Faculty of Medicine, The University of Queensland (Dr Walker), St Lucia.
Rachel Edwards
Rick Walker
John Roy
Andrew Paton
Claire M Rickard
Marie Cooke
Natalie Bradford
Victoria Gibson
Paula Cattanach
Rebecca S Paterson
Mari Takashima
Joshua Byrnes
Samantha Keogh
Tricia Kleidon
Paterson Public Schools · USQueensland Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCentral venous access devices (CVADs) are integral to cancer care provision. Despite the high prevalence of CVAD complications in children with cancer, preventative strategies are understudied.

objectiveThe aim of this study was to assess study feasibility, occlusive events, thrombolytic use, adverse events, and direct costs of catheter lock solutions.

methodsA single-center, parallel-group, pilot randomized controlled trial was undertaken at a tertiary-referral pediatric hospital in Australia. Children 18 years or younger with an oncological or malignant hematological condition and a CVAD were eligible. Participants were 1:1 randomized to (1) normal or (2) heparinized (10-100 U/mL; CVAD-type dependent) saline lock solutions.

resultsOf 217 children assessed for eligibility, 61 were recruited and randomized to normal (n = 30; 3850 CVAD days) or heparinized (n = 31; 4036 CVAD days) saline. Eligibility (52%) and recruitment (54%) feasibility targets were not met. Protocol adherence was high (95% assessments), with no attrition. Parent/clinician satisfaction of interventions was high (median, 10/10 clinicians/parents). Complete CVAD occlusion occurred in heparin only (n = 2, 6.7% CVADs; incidence rate [IR], 0.49/1000 CVAD days [0.06-1.78]). Central venous access device partial occlusion was detected in 23.3% of CVADs in heparin (n = 7; IR, 2.73/1000 CVAD days [1.36-4.87]) and 13.8% of CVADs in normal saline (n = 4; IR, 2.59/1000 CVAD days [1.24-4.77]). Thrombolytic agents were used in 16.7% heparin (5 CVADs) and 3.5% normal saline (1 CVAD). Adverse events did not differ between groups.

conclusionMultisite randomized controlled trials examining CVAD locks are safe, but strategies and resources to increase recruitment and eligibility are required. IMPLICATIONS FOR PRACTICE: Both routine CVAD lock solutions seem safe but may not prevent all forms of CVAD-associated harm.

Indexed as

Catheterization, Central VenousCatheter-Related InfectionsCentral Venous CathetersNeoplasmsChildFibrinolytic AgentsHeparinHumansPilot ProjectsSaline SolutionFibrinolytic AgentsHeparinSaline Solution

Identifiers

PMID35131974
PMCPMC9584054
OpenAlexW4210829411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.